Short Interest in Mainz Biomed NV (NASDAQ:MYNZ) Rises By 89.5%

Mainz Biomed NV (NASDAQ:MYNZ) was the recipient of a significant growth in short interest during the month of February. As of February 27th, there was short interest totaling 467,577 shares, a growth of 89.5% from the February 12th total of 246,769 shares. Based on an average daily volume of 1,043,162 shares, the days-to-cover ratio is currently 0.4 days. Currently, 5.2% of the company’s shares are short sold. Currently, 5.2% of the company’s shares are short sold. Based on an average daily volume of 1,043,162 shares, the days-to-cover ratio is currently 0.4 days.

Mainz Biomed Trading Down 8.4%

MYNZ stock traded down $0.07 on Thursday, reaching $0.77. The company’s stock had a trading volume of 5,239,299 shares, compared to its average volume of 575,532. The firm has a market cap of $7.00 million, a PE ratio of -0.01 and a beta of 0.31. The business has a fifty day simple moving average of $0.98 and a two-hundred day simple moving average of $1.25. Mainz Biomed has a 12-month low of $0.55 and a 12-month high of $5.34. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.43 and a current ratio of 0.52.

Institutional Investors Weigh In On Mainz Biomed

Several institutional investors and hedge funds have recently modified their holdings of the stock. Steward Partners Investment Advisory LLC increased its position in shares of Mainz Biomed by 200.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock valued at $34,000 after buying an additional 20,000 shares during the period. Armistice Capital LLC lifted its holdings in Mainz Biomed by 45.0% in the second quarter. Armistice Capital LLC now owns 285,000 shares of the company’s stock worth $402,000 after buying an additional 88,400 shares during the period. Finally, Cerity Partners LLC purchased a new stake in Mainz Biomed in the fourth quarter worth about $183,000.

Analysts Set New Price Targets

Several research analysts recently commented on MYNZ shares. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Mainz Biomed in a research note on Monday, December 22nd. Wall Street Zen raised shares of Mainz Biomed to a “hold” rating in a research report on Saturday, December 27th. Finally, Maxim Group lowered shares of Mainz Biomed from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce”.

About Mainz Biomed

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.